Laddar populära aktier...
Redeye leaves its initial comments on Lifecare following the announcement of raising NOK75-95m in gr...
Redeye has updated its estimates for Safeture following the Q1 2024 report.
Redeye updated its fair value range because of CLS’ reverse share split, where 200 existing shares h...
Q1(24) i korthet Nettoomsättningen under Q1(24) uppgick till 1,7 mkr (0,3) och övriga rörelseintäkte...
Redeye retains its positive view of Sdiptech following a Q1 report that was stronger than our expect...
Redeye’s view on the Q1 report. The organic growth was decent, while the gross margin development co...
Fiskars' Q1 adjusted EBIT was 13% above LSEG Data & Analytics consensus despite a 5% miss on sales.
Redeye initiates coverage of Precise Biometrics, a global leader in the fingerprint algorithms space...
Redeye takes a positive stance towards Fortnox following an overall solid Q1 report and the negative...
A miss, but keep in mind Q1 is ~5% of FY EBIT We cut '24e-'26e adj.
Redeye is encouraged to see a slightly higher-than-expected sales development for US CERAMENT G and ...
Orders -5%, sales +1%, adj. EBITA -7% vs. ABGSCe Some negative one-offs in quarter: system changes, ...
Redeye ger en kommentar om de preliminära Q1-siffrorna för Leqembi samt intryck från Biogens Q1-pres...
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
Redeye was hoping for a bit more in terms of top-line growth, but we are encouraged by strong gross ...